keyword
MENU ▼
Read by QxMD icon Read
search

CAR therapy

keyword
https://www.readbyqxmd.com/read/29329591/prospects-for-chimeric-antigen-receptor-modified-t-cell-therapy-for-solid-tumors
#1
REVIEW
Erhao Zhang, Jieyi Gu, Hanmei Xu
The potential for adoptive cell immunotherapy as a treatment against cancers has been demonstrated by the remarkable response in some patients with hematological malignancies using autologous T cells endowed with chimeric antigen receptors (CARs) specific for CD19. Clinical efficacy of CAR-T cell therapy for the treatment of solid tumors, however, is rare due to physical and biochemical factors. This review focuses on different aspects of multiple mechanisms of immunosuppression in solid tumors. We characterize the current state of CAR-modified T cell therapy and summarize the various strategies to combat the immunosuppressive microenvironment of solid tumors, with the aim of promoting T cell cytotoxicity and enhancing tumor cell eradication...
January 12, 2018: Molecular Cancer
https://www.readbyqxmd.com/read/29326190/a-qualitative-study-of-patients-feedback-about-outpatient-parenteral-antimicrobial-therapy-opat-services-in-northern-england-implications-for-service-improvement
#2
Maureen Twiddy, Carolyn J Czoski Murray, Samantha J Mason, David Meads, Judy M Wright, Elizabeth D Mitchell, Jane Minton
OBJECTIVE: Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation is patchy and a variety of service models are in use. The slow uptake in the UK and Europe is due to a number of clinical, financial and logistical issues, including concern about patient safety. The measurement of patient experience data is commonly used to inform commissioning decisions, but these focus on functional aspects of services and fail to examine the relational aspects of care...
January 10, 2018: BMJ Open
https://www.readbyqxmd.com/read/29326098/cognitive-and-behavioral-skills-exercises-completed-by-patients-with-major-depression-during-smartphone-cognitive-behavioral-therapy-secondary-analysis-of-a-randomized-controlled-trial
#3
Toshi A Furukawa, Masaru Horikoshi, Hirokazu Fujita, Naohisa Tsujino, Ran Jinnin, Yuki Kako, Sei Ogawa, Hirotoshi Sato, Nobuki Kitagawa, Yoshihiro Shinagawa, Yoshio Ikeda, Hissei Imai, Aran Tajika, Yusuke Ogawa, Tatsuo Akechi, Mitsuhiko Yamada, Shinji Shimodera, Norio Watanabe, Masatoshi Inagaki, Akio Hasegawa
BACKGROUND: A strong and growing body of evidence has demonstrated the effectiveness of cognitive behavioral therapy (CBT), either face-to-face, in person, or as self-help via the Internet, for depression. However, CBT is a complex intervention consisting of several putatively effective components, and how each component may or may not contribute to the overall effectiveness of CBT is poorly understood. OBJECTIVE: The aim of this study was to investigate how the users of smartphone CBT use and benefit from various components of the program...
January 11, 2018: JMIR Mental Health
https://www.readbyqxmd.com/read/29320890/chimeric-antigen-receptors-in-different-cell-types-new-vehicles-join-the-race
#4
Dennis C Harrer, Jan Dörrie, Niels Schaft
Adoptive cellular therapy has evolved into a powerful force in the battle against cancer, holding promise for curative responses in patients with advanced and refractory tumors. Autologous T cells, reprogrammed to target malignant cells via the expression of a chimeric antigen receptor (CAR) represent the frontrunner in this approach. Tremendous clinical regressions have been achieved using CAR-T cells against a variety of cancers both in numerous preclinical studies and in several clinical trials, most notably against ALL, and resulted in a very recent FDA-approval of the first CAR-T-cell therapy...
January 10, 2018: Human Gene Therapy
https://www.readbyqxmd.com/read/29317339/from-clinical-proof-of-concept-to-commercialization-of-car-t-cells
#5
Boris Calmels, Bechara Mfarrej, Christian Chabannon
The development of CAR T cells currently represents an exciting opportunity to convert the already published clinical successes observed in clinical trials into commercially available efficient therapies. However, the path toward successful commercialization is still hindered by many hurdles. Here, we review such issues as: the need for structured collaborations between hospital collection and clinical facilities and industry manufacturing facilities to streamline the supply chain; necessity for uniform and efficient medical procedures to cope with severe toxicities associated with CAR T cells; and absolute need to define an economical and sustainable model for manufacturers and payers...
January 6, 2018: Drug Discovery Today
https://www.readbyqxmd.com/read/29316527/contrasting-effects-of-individual-versus-combined-estrogen-and-progestogen-regimens-as-working-memory-load-increases-in-middle-aged-ovariectomized-rats-one-plus-one-does-not-equal-two
#6
Alesia V Prakapenka, Ryoko Hiroi, Alicia M Quihuis, Catie Carson, Shruti Patel, Claire Berns-Leone, Carly Fox, Rachael W Sirianni, Heather A Bimonte-Nelson
Most estrogen-based hormone therapies are administered in combination with a progestogen, such as Levonorgestrel (Levo). Individually, the estrogen 17β-estradiol (E2) and Levo can improve cognition in preclinical models. However, although these hormones are often given together clinically, the impact of the E2 + Levo combination on cognitive function has yet to be methodically examined. Thus, we investigated E2 + Levo treatment on a cognitive battery in middle-aged, ovariectomized rats. When administered alone, E2 and Levo treatments each enhanced spatial working memory relative to vehicle treatment, whereas the E2 + Levo combination impaired high working memory load performance relative to E2 only and Levo only treatments...
December 7, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/29311388/chimeric-antigen-receptor-t-cell-therapy-challenges-to-bench-to-bedside-efficacy
#7
REVIEW
Shivani Srivastava, Stanley R Riddell
Immunotherapy with T cells genetically modified to express chimeric Ag receptors (CARs) that target tumor-associated molecules have impressive efficacy in hematological malignancies. The field has now embraced the challenge of applying this approach to treat common epithelial malignancies, which make up the majority of cancer cases but evade immunologic attack by a variety of subversive mechanisms. In this study, we review the principles that have guided CAR T cell design and the extraordinary clinical results being achieved in B cell malignancies targeting CD19 with a single infusion of engineered T cells...
January 15, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29310899/efficacy-safety-and-tolerability-of-dolutegravir-rilpivirine-for-the-maintenance-of-virological-suppression-in-adults-with-hiv-1-phase-3-randomised-non-inferiority-sword-1-and-sword-2-studies
#8
Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, Francesco Castelli, Pierre-Marie Girard, Lesley P Kahl, Elizabeth A Blair, Kostas Angelis, Brian Wynne, Kati Vandermeulen, Mark Underwood, Kim Smith, Martin Gartland, Michael Aboud
BACKGROUND: Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug regimens to minimise cumulative drug exposure and toxicities. The safety, tolerability, and efficacy of dolutegravir and rilpivirine suggest potential compatibility and effectiveness as a two-drug regimen. We aimed to investigate this two-drug regimen in a phase 3 study. METHODS: We identically designed SWORD-1 and SWORD-2, which were open-label, parallel-group, multicentre, phase 3, randomised, non-inferiority studies in 12 countries evaluating efficacy and safety of once-daily dolutegravir 50 mg plus rilpivirine 25 mg versus current ART regimen (CAR)...
January 5, 2018: Lancet
https://www.readbyqxmd.com/read/29301772/cd19-car-t-therapy-and-sepsis-dancing-with-the-devil
#9
Lihua E Budde, John A Zaia
No abstract text is available yet for this article.
January 4, 2018: Blood
https://www.readbyqxmd.com/read/29298689/anti-gd2-4-1bb-chimeric-antigen-receptor-t-cell-therapy-for-the-treatment-of-chinese-melanoma-patients
#10
Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong, Jun Guo
BACKGROUND: Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell therapy in the treatment of other solid tumors has been limited. We incorporated 4-1BB into the anti-GD2 CAR-T cells to test their cytotoxicity in melanoma in vitro and in vivo. Moreover, we reported the expression of ganglioside GD2 in non-Caucasian melanoma populations for the first time, thus providing a basis for future clinical research...
January 3, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29288199/comparison-of-t-cell-activities-mediated-by-human-tcrs-and-cars-that-use-the-same-recognition-domains
#11
Daniel T Harris, Marlies V Hager, Sheena N Smith, Qi Cai, Jennifer D Stone, Philipp Kruger, Melissa Lever, Omer Dushek, Thomas M Schmitt, Philip D Greenberg, David M Kranz
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic cancers. Two types of receptor systems have been used to redirect the activity of T cells, normal heterodimeric TCRs or synthetic chimeric Ag receptors (CARs). TCRs recognize peptide-HLA complexes whereas CARs typically use an Ab-derived single-chain fragments variable that recognizes cancer-associated cell-surface Ags. Although both receptors mediate diverse effector functions, a quantitative comparison of the sensitivity and signaling capacity of TCRs and CARs has been limited due to their differences in affinities and ligands...
December 29, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29288188/efficacy-and-safety-of-chimeric-antigen-receptor-t-cell-car-t-therapy-in-patients-with-haematological-and-solid-malignancies-protocol-for-a-systematic-review-and-meta-analysis
#12
Emma J M Grigor, Dean A Fergusson, Fatima Haggar, Natasha Kekre, Harold Atkins, Risa Shorr, Robert A Holt, Brian Hutton, Tim Ramsay, Matthew Seftel, Derek Jonker, Mads Daugaard, Kednapa Thavorn, Justin Presseau, Manoj M Lalu
INTRODUCTION: Patients with relapsed or refractory malignancies have a poor prognosis. Immunotherapy with chimeric antigen receptor T (CAR-T) cells redirects a patient's immune cells against the tumour antigen. CAR-T cell therapy has demonstrated promise in treating patients with several haematological malignancies, including acute B-cell lymphoblastic leukaemia and B-cell lymphomas. CAR-T cell therapy for patients with other solid tumours is also being tested. Safety is an important consideration in CAR-T cell therapy given the potential for serious adverse events, including death...
December 29, 2017: BMJ Open
https://www.readbyqxmd.com/read/29285731/therapeutic-cancer-vaccines-how-much-closer-are-we
#13
Douglas G McNeel
The promise of immune-based therapies to treat cancer has been realized over the last several years with several breakthrough therapies, including T-cell checkpoint inhibitors and chimeric antigen receptor (CAR)-T cell therapies. While cancer vaccines have been investigated for many decades, to date only one has been approved in the USA as a treatment for existing cancer. The failure of several anti-tumor vaccines in large phase III trials has led many to question their future role in cancer treatment. Trials to date have demonstrated that many cancer vaccines can elicit tumor-specific T cells, but these T cells may be insufficient to mediate substantial anti-tumor effects without concurrent blockade of tumor-resistance mechanisms...
December 28, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29285651/a-long-term-survival-case-treated-with-conversion-surgery-following-chemotherapy-after-diagnostic-metastasectomy-for-pancreatic-cancer-with-synchronous-liver-metastasis
#14
Mitsuhiro Shimura, Masamichi Mizuma, Hiroki Hayashi, Akiko Mori, Tomoyoshi Tachibana, Tatsuo Hata, Masahiro Iseki, Tatsuyuki Takadate, Kyohei Ariake, Shimpei Maeda, Hideo Ohtsuka, Naoaki Sakata, Takanori Morikawa, Kei Nakagawa, Takeshi Naitoh, Takashi Kamei, Fuyuhiko Motoi, Michiaki Unno
BACKGROUND: Pancreatic cancer with distant metastases is classified as "unresectable," for which the standard treatment is systemic chemotherapy. The effectiveness of radical resection for pancreatic cancer with distant metastases is unknown. Here, we report a case of long term survival treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. CASE PRESENTATION: A 73-year-old man was referred to our hospital to examine and treat for cancer of the pancreatic body...
December 29, 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/29284044/long-term-persistence-and-function-of-hematopoietic-stem-cell-derived-chimeric-antigen-receptor-t-cells-in-a-nonhuman-primate-model-of-hiv-aids
#15
Anjie Zhen, Christopher W Peterson, Mayra A Carrillo, Sowmya Somashekar Reddy, Cindy S Youn, Brianna B Lam, Nelson Y Chang, Heather A Martin, Jonathan W Rick, Jennifer Kim, Nick C Neel, Valerie K Rezek, Masakazu Kamata, Irvin S Y Chen, Jerome A Zack, Hans-Peter Kiem, Scott G Kitchen
Chimeric Antigen Receptor (CAR) T-cells have emerged as a powerful immunotherapy for various forms of cancer and show promise in treating HIV-1 infection. However, significant limitations are persistence and whether peripheral T cell-based products can respond to malignant or infected cells that may reappear months or years after treatment remains unclear. Hematopoietic Stem/Progenitor Cells (HSPCs) are capable of long-term engraftment and have the potential to overcome these limitations. Here, we report the use of a protective CD4 chimeric antigen receptor (C46CD4CAR) to redirect HSPC-derived T-cells against simian/human immunodeficiency virus (SHIV) infection in pigtail macaques...
December 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/29282693/new-approaches-in-car-t-cell-immunotherapy-for-breast-cancer
#16
Jinghua Wang, Penghui Zhou
Despite significant advances in surgery, chemotherapy, radiotherapy, endocrine therapy, and molecular-targeted therapy, breast cancer remains the leading cause of death from malignant tumors among women. Immunotherapy has recently become a critical component of breast cancer treatment with encouraging activity and mild safety profiles. CAR-T therapy using genetically modifying T cells with chimeric antigen receptors (CAR) is the most commonly used approach to generate tumor-specific T cells. It has shown good curative effect for a variety of malignant diseases, especially for hematological malignancies...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29276275/chimeric-antigen-receptor-t-cell-therapy-for-lymphomas
#17
Benjamin Jolley, Scot Walker
It is estimated that 2.1% of the population of the United States will develop non-Hodgkin lymphoma (NHL) in a lifetime. With treatment, 71% of patients with NHL live to 5 years. Because current drugs used for treatment do not cure all patients and cause serious adverse effects, new strategies have been studied to treat lymphoma. One new pharmacologic strategy is to use chimeric antigen receptor T-cell (CAR T-cell) therapy. CAR T-cell therapies are very potent. As a class, the CAR T-cell therapies have induced complete remission in 50% to 80% of patients...
July 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29275235/endovascular-treatment-of-renal-arterial-perforation-after-blunt-trauma-case-report
#18
Kyoung Hoon Lim, Hun Kyu Ryeom, Jinyoung Park
INTRODUCTION: Isolated renal arterial perforation is a rare consequence of blunt abdominal trauma. Meticulous surgical control of retroperitoneal active bleeding is difficult due to oozing of soft connective tissue, the deep position of operative field, and the presence of friable vascular tissue. Therefore, endovascular treatment is often preferred. PRESENTATION OF CASE: An 83-year-old man was transferred to our trauma center due to retroperitoneal active bleeding after a car accident, in which his right upper abdomen struck the steering wheel...
December 16, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29249304/car-t-cell-therapy-in-refractory-large-b-cell-lymphoma
#19
Robert Stirrups
No abstract text is available yet for this article.
December 14, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29248427/car-t-cells-a-systematic-review-and-mixed-methods-analysis-of-the-clinical-trial-landscape
#20
REVIEW
David Pettitt, Zeeshaan Arshad, James Smith, Tijana Stanic, Georg Holländer, David Brindley
CAR-T cells are a promising new therapy that offer significant advantages compared with conventional immunotherapies. This systematic review and clinical trial landscape identifies and critiques published CAR-T cell clinical trials and examines the critical factors required to enable CAR-T cells to become a standard therapy. A review of the literature was conducted to identify suitable studies from the MEDLINE and Ovid bibliographic databases. The literature and database searches identified 20 studies for inclusion...
November 2, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
keyword
keyword
37051
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"